Toronto Dominion Bank Takes $11.03 Million Position in Protara Therapeutics, Inc. (NASDAQ:TARA)

Toronto Dominion Bank acquired a new stake in Protara Therapeutics, Inc. (NASDAQ:TARA - Free Report) during the fourth quarter, according to its most recent filing with the SEC. The firm acquired 2,088,937 shares of the company's stock, valued at approximately $11,030,000. Toronto Dominion Bank owned about 10.13% of Protara Therapeutics at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the company. Oppenheimer & Co. Inc. boosted its holdings in shares of Protara Therapeutics by 12.4% in the fourth quarter. Oppenheimer & Co. Inc. now owns 201,426 shares of the company's stock valued at $1,064,000 after acquiring an additional 22,301 shares in the last quarter. Bailard Inc. acquired a new stake in Protara Therapeutics in the fourth quarter valued at about $157,000. Commonwealth Equity Services LLC boosted its holdings in Protara Therapeutics by 90.4% in the 4th quarter. Commonwealth Equity Services LLC now owns 37,000 shares of the company's stock valued at $195,000 after purchasing an additional 17,572 shares in the last quarter. Geode Capital Management LLC increased its position in Protara Therapeutics by 5.6% during the 4th quarter. Geode Capital Management LLC now owns 179,593 shares of the company's stock worth $948,000 after purchasing an additional 9,553 shares during the period. Finally, ADAR1 Capital Management LLC purchased a new position in shares of Protara Therapeutics during the 4th quarter worth approximately $648,000. 38.13% of the stock is currently owned by hedge funds and other institutional investors.

Protara Therapeutics Trading Down 1.3%

Shares of TARA stock traded down $0.04 during mid-day trading on Friday, reaching $3.13. The stock had a trading volume of 372,832 shares, compared to its average volume of 770,777. The company has a market cap of $120.76 million, a P/E ratio of -1.11 and a beta of 1.73. Protara Therapeutics, Inc. has a 12-month low of $1.60 and a 12-month high of $10.48. The business has a 50-day simple moving average of $3.86 and a 200 day simple moving average of $4.14.

Protara Therapeutics (NASDAQ:TARA - Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported ($0.29) earnings per share for the quarter, beating the consensus estimate of ($0.47) by $0.18. Research analysts anticipate that Protara Therapeutics, Inc. will post -3.32 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on TARA. Scotiabank started coverage on Protara Therapeutics in a research note on Wednesday, April 16th. They issued a "sector outperform" rating and a $12.00 price target on the stock. Jones Trading started coverage on shares of Protara Therapeutics in a research report on Thursday. They set a "buy" rating and a $21.00 target price on the stock. HC Wainwright reaffirmed a "buy" rating and set a $23.00 price target on shares of Protara Therapeutics in a research note on Monday, April 28th. Cantor Fitzgerald started coverage on shares of Protara Therapeutics in a research note on Friday, March 14th. They issued an "overweight" rating for the company. Finally, Lifesci Capital initiated coverage on shares of Protara Therapeutics in a report on Tuesday, March 11th. They set an "outperform" rating and a $22.00 price objective on the stock. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has an average rating of "Buy" and a consensus price target of $20.50.

Insider Activity

In related news, insider Jacqueline Zummo sold 21,224 shares of Protara Therapeutics stock in a transaction that occurred on Wednesday, March 26th. The stock was sold at an average price of $4.53, for a total transaction of $96,144.72. Following the completion of the transaction, the insider now directly owns 98,861 shares in the company, valued at $447,840.33. The trade was a 17.67% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 8.40% of the company's stock.

About Protara Therapeutics

Protara Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.